英夫利西单抗联合肠内营养在中重度溃疡性结肠炎治疗中的临床价值

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1360 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To observe the clinical value of infliximab combined with enteral nutrition (EN) in the treatment of moderate to severe ulcerative colitis (UC). Methods: A total of 20 patients with moderate to severe UC who showed no response to traditional therapies were selected in this study. These UC patients were treated with intravenous micropump of infliximab at a dose of 5 mg/kg for 6 times, combined EN treatment for 3 months and oral azathioprine for maintenance treatment. Results: After treatment, the body mass index (BMI), hemoglobin (Hb) and serum albumin (ALB) in UC patients were all significantly increased than those before treatment (all P<0.05), while the modified Mayo score, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cell count (WBC) in UC patients were all lower than those before treatment (all P<0.05). A total of 16 UC patients showed effective response to the treatment, of whom 15 UC patients achieved clinical remission and 12 UC patients achieved mucosal healing. Followed up for 6 to 24 months, 1 UC patient developed malignant lymphoma, 1 UC patient had a relapse after withdrawal of azathioprine, and the remaining patients had good disease control without recurrence. Conclusion: Infliximab combined with EN-induced clinical remission and maintenance therapy with azathioprine could have good clinical efficacy in the treatment of moderate to severe UC, and it also could improve the prognosis of UC patients.

Key words： infliximab enteral nutrition ulcerative colitis treatment azathioprine

Received: 03 March 2018

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHAO Xiaoxiao
	CAO Jiale
	YU Lingmin
	JIANG Yi.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2018/V48/I9/684

[1] WANG Y F, OUYANG Q, HU R W. Progression of inflammatory bowel disease in China[J]. J Dig Dis, 2010, 11(2): 76-82.
[2] HIRSCHMANN S, NEURATH M F. Top-down approach to biological therapy of Crohn’s disease[J]. Expert Opin Biol Ther, 2017, 17(3): 285-293.
[3] GROVER Z, MUIR R, LEWINDON P, et al. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease[J]. J Gastroenterol, 2014, 49(4): 638-645.
[4] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2012年,广州)[J]. 中华消化杂志, 2012, 32(12): 796-813.
[5] XU X R, LIU C Q, FENG B S, et al. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease[J].World J Gastroenterol, 2014, 20(12): 3255-3264.
[6] GROVER Z, MUIR R, LEWINDON P, et al. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease[J]. J Gastroenterol, 2014, 49(4): 638-645.
[7] THANAPATI S, GANU M, GIRI P, et al. Impaired NK cell functionality and increased TNF-α production as biomarkers of chronic chikungunya arthritis and rheumatoid arthritis[J]. Hum Immunol, 2017, 78(4): 370-374.
[8] MOSCA M, TANI C, FILICE M E, et al. TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review[J]. Mod Rheumatol, 2015, 25 (4): 642-645.
[9] CHITUL A, VOIOSU A M, MARINESCU M, et al. Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis[J]. Rom J Intern Med, 2017, 55(1): 44-52.
[10] DANESH M J, KOO E B, KIMBALL A B. Effects of TNF-alpha antagonism in patients with metabolic syndrome and psoriasis[J]. J Eur Acad Dermatol Venereol, 2016, 30(11): e152-e154.
[11] MARINI J C, SENDECKI J, CORNILLIE F, et al. Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade®[J]. AAPS J, 2017, 19(1): 161-171.
[12] RUTGEERTS P, VERMEIRE S, VAN ASSCHE G. Biological therapies for inflammatory bowel diseases[J]. Gastroenterology, 2009, 136: 1182-1197.
[13] COTTONE M, MOCCIARO F, ORLANDO A. Infliximab prevents Crohn’s disease recurrence after ileal resection[J]. Expert Rev Gastroenterol Hepatol, 2009, 3(3): 231-234.
[14] FIORINO G, BONOVAS S, CICERONE C, et al. The safety of biological pharmacotherapy for the treatment of ulcerative colitis[J]. Expert Opin Drug Saf, 2017, 16(4): 437-443.
[15] 李世荣, 陆晓娟, 盛剑秋, 等. 溃疡性结肠炎和克罗恩的英夫利西(类克)治疗效果比较[J]. 胃肠病学和肝病学杂志, 2010, 19(7): 644-647.
[16] RADIN M, SCIASCIA S, ROCCATELLO D, et al. Infliximab biosimilars in the treatment of inflammatory bowel diseases: A systematic review[J]. Bio Drugs, 2017, 31(1): 37-49.
[17] ALTOMARE R, DAMIANO G, ABRUZZO A, et al. Enteral nutrition support to treat malnutrition in inflammatory bowel disease[J]. Nutrients, 2015, 7(4): 2125-2133.